Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

(2014) J. E. Abraham et al.   CLINICAL CANCER RESEARCH

Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer

(2013) L. Eckhoff et al.   BREAST CANCER RESEARCH AND TREATMENT

Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis

(2013) Zhi Peng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer

(2012) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization

(2011) David André Barrière et al.   PAIN

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

(2010) Dawn L. Hershman et al.   BREAST CANCER RESEARCH AND TREATMENT

Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients

(2010) Roberta Rizzo et al.   BREAST CANCER RESEARCH AND TREATMENT

Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity

(2009) O. Mir et al.   ANNALS OF ONCOLOGY

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study

(2009) Hee Seung Kim et al.   GYNECOLOGIC ONCOLOGY

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

(2009) J F Deeken et al.   PHARMACOGENOMICS JOURNAL

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

(2008) T. M. Sissung et al.   CLINICAL CANCER RESEARCH

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

(2008) SD Baker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

No Evidence for Taxane/Platinum Pharmacogenetic Markers: Just Lack of Power?

(2008) Werner Vach et al.   JOURNAL OF CLINICAL ONCOLOGY